Shikonin has been demonstrated to target the SH2 domain of STAT3 resulting in the suppression of IL-17-induced vascular endothelial growth factor (VEGF) expression, sensitization to gefitinib and the induction of tumour cell apoptosis [154,155,156,157]. The gene discussed is STAT3; the disease is neoplasm.